Healthcare provider profile · identity verified

Oded Zmora, M.D.

Family Practice · CINCINNATI, OH · NPI 1750485207

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	302	97
Gabapentin	Gabapentin	181	47
Levothyroxine Sodium	Levothyroxine Sodium	169	56
Amlodipine Besylate	Amlodipine Besylate	149	47
Metformin Hcl	Metformin Hcl	120	41
Losartan Potassium	Losartan Potassium	86	25
Rosuvastatin Calcium	Rosuvastatin Calcium	86	28
Lisinopril	Lisinopril	82	27
Pantoprazole Sodium	Pantoprazole Sodium	82	24
Omeprazole	Omeprazole	80	25
Metoprolol Succinate	Metoprolol Succinate	74	27
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	70	15
Simvastatin	Simvastatin	66	21
Zolpidem Tartrate	Zolpidem Tartrate	64	15
Metoprolol Tartrate	Metoprolol Tartrate	59	17
Albuterol Sulfate Hfa	Albuterol Sulfate	58	32
Tamsulosin Hcl	Tamsulosin Hcl	56	18
Eliquis	Apixaban	52	14
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	49	18
Alprazolam	Alprazolam	47	suppressed
Prednisone	Prednisone	45	32
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	44	17
Mounjaro	Tirzepatide	42	suppressed
Ozempic	Semaglutide	42	suppressed
Trazodone Hcl	Trazodone Hcl	42	15
Escitalopram Oxalate	Escitalopram Oxalate	41	suppressed
Fluticasone Propionate	Fluticasone Propionate	41	11
Pioglitazone Hcl	Pioglitazone Hcl	41	14
Spironolactone	Spironolactone	41	suppressed
Metformin Hcl Er	Metformin Hcl	40	11
Jardiance	Empagliflozin	39	suppressed
Trulicity	Dulaglutide	38	11
Symbicort	Budesonide/Formoterol Fumarate	37	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	35	11
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	33	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	33	14
Meloxicam	Meloxicam	32	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	32	suppressed
Allopurinol	Allopurinol	31	suppressed
Atenolol	Atenolol	30	suppressed
Carvedilol	Carvedilol	30	12
Montelukast Sodium	Montelukast Sodium	29	suppressed
Tizanidine Hcl	Tizanidine Hcl	29	suppressed
Diazepam	Diazepam	28	suppressed
Clopidogrel	Clopidogrel Bisulfate	26	suppressed
Alendronate Sodium	Alendronate Sodium	25	suppressed
Glipizide	Glipizide	25	suppressed
Ipratropium Bromide	Ipratropium Bromide	25	15
Pravastatin Sodium	Pravastatin Sodium	25	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	25	suppressed
Clonazepam	Clonazepam	24	suppressed
Diclofenac Sodium	Diclofenac Sodium	24	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	24	suppressed
Ondansetron Hcl	Ondansetron Hcl	24	suppressed
Sertraline Hcl	Sertraline Hcl	24	suppressed
Potassium Chloride	Potassium Chloride	23	suppressed
Duloxetine Hcl	Duloxetine Hcl	22	suppressed
Droplet Pen Needle	Pen Needle, Diabetic	21	suppressed
Famotidine	Famotidine	21	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	21	suppressed
Paroxetine Hcl	Paroxetine Hcl	21	suppressed
Januvia	Sitagliptin Phosphate	20	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	18	16
Methocarbamol	Methocarbamol	18	13
Tramadol Hcl	Tramadol Hcl	18	suppressed
Zolpidem Tartrate Er	Zolpidem Tartrate	18	suppressed
Levemir Flexpen	Insulin Detemir	17	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	17	16
Promethazine Hcl	Promethazine Hcl	17	suppressed
Breo Ellipta	Fluticasone/Vilanterol	16	suppressed
Celecoxib	Celecoxib	16	suppressed
Humulin N	Insulin Nph Human Isophane	16	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	16	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	16	suppressed
Citalopram Hbr	Citalopram Hydrobromide	15	suppressed
Furosemide	Furosemide	15	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	15	suppressed
Spiriva Respimat	Tiotropium Bromide	15	suppressed
Valacyclovir	Valacyclovir Hcl	15	suppressed
Valsartan	Valsartan	15	suppressed
Bupropion Xl	Bupropion Hcl	14	suppressed
Carisoprodol	Carisoprodol	14	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	14	13
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	14	suppressed
Hydrocortisone	Hydrocortisone	14	suppressed
Nifedipine Er	Nifedipine	14	suppressed
Xarelto	Rivaroxaban	14	suppressed
Finasteride	Finasteride	13	suppressed
Lidocaine	Lidocaine	13	suppressed
Livalo	Pitavastatin Calcium	13	suppressed
Myrbetriq	Mirabegron	13	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	13	suppressed
Tretinoin	Tretinoin	13	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	12	suppressed
Baclofen	Baclofen	12	suppressed
Glimepiride	Glimepiride	12	suppressed
Ibuprofen	Ibuprofen	12	suppressed
Ondansetron Odt	Ondansetron	12	suppressed
Ramipril	Ramipril	12	suppressed
Ropinirole Hcl	Ropinirole Hcl	12	suppressed
Steglatro	Ertugliflozin Pidolate	12	suppressed
Temazepam	Temazepam	12	suppressed
Tradjenta	Linagliptin	12	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	11	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	11	suppressed
Clonidine Hcl	Clonidine Hcl	11	suppressed
Colchicine	Colchicine	11	suppressed
Donepezil Hcl	Donepezil Hcl	11	suppressed
Ezetimibe	Ezetimibe	11	suppressed
Glipizide Er	Glipizide	11	suppressed
Insulin Aspart Flexpen	Insulin Aspart	11	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	11	suppressed
Prazosin Hcl	Prazosin Hcl	11	suppressed
Terazosin Hcl	Terazosin Hcl	11	suppressed
Ultra-Fine Micro Pen Needle	Pen Needle, Diabetic	11	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	11	suppressed
Verapamil Er	Verapamil Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error